TREM2 Recombinant Proteins and Flow Cyt Antibodies

TREM2 stands for Triggering Receptor Expressed on Myeloid Cells 2. It is a single-pass immunoglobulin superfamily receptor predominantly expressed in microglia, macrophages, monocytes, and osteoclasts. Through its signaling complex with DAP12/TYROBP, TREM2 regulates cell survival, migration, phagocytic clearance, inflammatory modulation, and tissue homeostasis. In the central nervous system, TREM2 is particularly important for sensing and clearing amyloid-beta, apoptotic debris, and other pathological material, making it a central target in neurodegeneration and neuroinflammation research.

From a drug-development perspective, TREM2 is a high-interest but still challenging translational target. Currently, there are approximately 50 TREM2-targeted programs reported globally. The leading therapeutic modalities are currently agonistic monoclonal antibodies and small-molecule agonists. By early 2025, three agonistic anti-TREM2 monoclonal antibodies had entered clinical trials, and small-molecule TREM2 agonists had also moved into clinical development. Additional approaches under exploration include bispecific antibodies, CAR-T therapies, nanobodies, gene therapies, and diagnostic radiotracers. The main disease focus remains Alzheimer’s disease, with expansion into rare leukodystrophies, ALS, Parkinson’s disease, and frontotemporal dementia. For detailed therapeutic progress, readers can further visit “Targeting TREM2: Mechanisms, Diseases, and Drug Development“.

DIMA BIOTECH provides an integrated portfolio of TREM2 research tools, including extracellular domain recombinant proteins, a full-length membrane protein in synthetic nanodiscs, Flow Cyt monoclonal antibodies, and reference antibodies. Multi-species TREM2 ECD recombinant proteins covering Human, Mouse, and Cynomolgus are well suited for immunogen preparation, antibody screening, and receptor-ligand binding studies; the Human TREM2 full-length protein-synthetic nanodisc is more suitable for native-conformation-dependent binding, membrane-proximal epitope recognition, and mechanism studies; and the monoclonal antibodies validated for ELISA and Flow Cyt support cell-surface expression analysis and flow cytometry applications. Together, these products create a practical workflow from recombinant antigen preparation to cell-based validation.